Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

CLRB holding history

Cellectar Biosciences, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CLRB overviewAll 13F holders of CLRBFull Q2 2026 holdings

Shares (Q2 2026)
3,093
Value
$8.60K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of CLRB by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20263,093$8.60K<0.1%−6,554−67.9%ReducedHolders
Q1 20269,647$24.5K<0.1%+7,049+271.3%AddedHolders
Q4 20252,598$7.66K<0.1%+1,690+186.1%AddedHolders
Q3 2025908$5.08K<0.1%−2,712−74.9%ReducedHolders
Q2 20253,620$25.7K<0.1%−916,732−99.6%ReducedHolders
Q1 2025920,352$289.9K<0.1%+544,153+144.6%AddedHolders
Q4 2024376,199$112.5K<0.1%+373,622+14,498.3%AddedHolders
Q3 20242,577$5.51K<0.1%−12,223−82.6%ReducedHolders
Q2 202414,800$37.0K<0.1%+8,850+148.7%AddedHolders
Q1 20245,950$23.7K<0.1%+4,750+395.8%AddedHolders
Q4 20231,200$3.32K<0.1%−56−4.5%ReducedHolders
Q3 20231,256$3.32K<0.1%+56+4.7%AddedHolders
Q2 20231,200$2.34K<0.1%−910−43.1%ReducedHolders
Q1 20232,110$3.02K<0.1%+460+27.9%AddedHolders
Q4 20221,650$2.82K<0.1%00.0%UnchangedHolders
Q3 20221,650$6.00K<0.1%−2,314−58.4%ReducedConverted for a 1-for-10 splitHolders
Q2 202239,642$16.0K<0.1%+23,142+140.3%AddedHolders
Q1 202216,500$11.0K<0.1%−35,458−68.2%ReducedHolders
Q4 202151,958$34.0K<0.1%+40,458+351.8%AddedHolders
Q3 202111,500$11.0K<0.1%00.0%UnchangedHolders
Q2 202111,500$14.0K<0.1%+9,500+475.0%AddedHolders
Q1 20212,000$3.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.